Showing results (131-140 of 154) with videos related to
Sort By:
Pageof 16
Immunotherapy Advances|August 3, 2022
Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancersAaron J Harrison, Xin Du, Bianca von Scheidt, et al.Immunotherapy Advances|February 2, 2023
Peripheral blood persistence and expansion of transferred non-genetically modified Natural Killer cells might not be necessary for clinical activityLucia SillaImmunotherapy Advances|August 15, 2022
Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impactSifan Zhang, Becca Asquith, Richard Szydlo, et al.Immunotherapy Advances|August 2, 2022
Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapyDongyan Zhou, Runhong Zhou, Zhiwei ChenImmunotherapy Advances|August 21, 2025
Applying population mechanistic modelling to find determinants of chimeric antigen receptor T-cells dynamics in month-one lymphoma patientsLiam V Brown, Mark McConnell, Robert Rosler, et al.Immunotherapy Advances|January 23, 2026
Targeting intratumoral regulatory T cells by CD137 aptamer-shRNA chimerasKang Yi Lee, Yu Mei, Haiyan Liu, et al.Immunotherapy Advances|December 25, 2025
[89Zr]Zr-DFO-avelumab accumulation in resectable non-small cell lung carcinoma indicates a suppressive tumor microenvironment amendable to neoadjuvant avelumab treatmentSarah R Verhoeff, Evelien A J van Genugten, Iris A E van der Hoorn, et al.Immunotherapy Advances|June 30, 2025
Comparing DC subsets in solid tumors: what about DC3s?Casper J Pachocki, Marianne Boes, Alsya J AffandiImmunotherapy Advances|May 12, 2025
Lag3 and PD-1 pathways preferentially regulate NFAT-dependent TCR signalling programmes during early CD4+ T cell activationLozan Sheriff, Alastair Copland, David A J Lecky, et al.Immunotherapy Advances|July 17, 2025
Cytokine-induced memory-like NK cells combined with Tafasitamab demonstrate efficacy against B-cell acute lymphoblastic leukemiaDimitrios Filioglou, Geovana S F Leite, Helena Batatinha, et al.Pageof 16